▶ Established in 1994, the Korean Academy of Oral & Maxillofacial Implantology is the largest dental society in Korea with more than 4,800 members.

▶ Signed a business agreement to develop the domestic implant industry with Plasmapp's innovative technology

Plasmapp (405000) announced on April 18 that it participated in the 16th inauguration ceremony of the Korean Academy of Oral & Maxillofacial Implantology (KAOMI), the largest dental society in Korea, and signed a business agreement to support research and education in plasma technology with the goal of developing the implant industry.

KAOMI, founded in 1994 and the largest dental society in Korea with more than 4,800 members, leads the world's dental implant industry based on bioethics and strives to improve the oral health of the people through creative research and continuous education. By encompassing the tradition of dental implant surgery and the cutting-edge technology that is changing to fit the digital age, KAOMI leads industry-academia collaboration through the KAOMI Implant Research Center to develop the domestic implant industry and share the benefits with the public.

Under the agreement, industry-academia collaboration with KAOMI Implant Research Institute will be conducted to conduct joint research on clinical validation of plasma technology for peri-implantitis treatment and surface treatment technology, and related knowledge and information will be shared through KAOMI's general conferences. In addition, the two organizations will strengthen cooperation in publishing Plasmapp's research results to help the Korean Academy of Oral & Maxillofacial Implantology Surgeons become an SCI-level international journal.

Plasmapp has developed a plasma surface treatment machine (brand: ACTILINK) that enables safer and more efficient treatment of dental implants, and is rapidly expanding its commercialization in the global dental market by verifying clinical benefits in collaboration with top clinical research institutes at home and abroad. Recently, Plasmapp has developed the world's first innovative plasma stimulation treatment device (brand: STIMLINK) that can treat peri-implantitis by delivering electrical stimulation to the implant to increase the initial stability of the implant, and has begun full-scale technical and clinical validation.

"Plasmapp's technology can create a paradigm shift in the global implant industry," said Dr. Jaehong Hwang, President of KAOMI. "Based on this agreement, we will work with KAOMI Implant Research Institute to develop the domestic implant industry and contribute to increasing the competitiveness of Korean medical device technology in the global market."

"With the launch of the surface activator in 2021, we generated more than double sales growth every year in 2021 and 2022, and we will generate double growth again every year until next year with the stimulation therapy device that we will launch this year," said Youbong Lim, CEO of Plasmapp. "Through this business agreement with KAOMI, we will quickly expand plasma technology in the domestic dental market, conduct clinical verification and optimization, and rapidly expand to the global market."